Skip to contents

  1. Phạm Hanh [Director]; Nguyet Toat [Other]; Cao Van Thuan [Other]; Van Ngu [Other]; Nguyen Hoan [Editor]; Van Ky [Other]; Nhu Cuong [Other]; Tran Khac An [Producer]; Le Kim Trong [Producer] ; Vietnam People's Armed Forces Studios, Adam Matthew Digital (Firm)

    Ben Hai People

    Books
    View online
    Schließen
    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    Marlborough, Wiltshire: Adam Matthew Digital, 2017

    Published in: Socialism on Film- The Vietnam War & Southeast Asia- Wars & Revolutions

  13. Gogate, Anagha; Crosbie, Amanda; Le, Trong Kim; Zhang, Ying; Das, Rolee; Davis, Catherine

    Abstract P3-12-15: Clinical characteristics, treatment patterns, and survival outcomes in women with early triple-negative (TN) or hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2−) breast cancer (BC) in the real-world (RW) setting

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Association for Cancer Research (AACR), 2022

    Published in: Cancer Research

  15. Awan, Farrukh T.; Deshpande, Gaurav A.; Le, Trong Kim; Garrison, Sean; Tiwana, Simran K.; Priyadarshini, Masoom

    Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Hematology, 2022

    Published in: Blood

  19. Jabbour, Elias J.; You, Min; Le, Trong Kim; Brokars, John; Brun, Alexander; Makenbaeva, Dinara

    Prevalence of Comorbidities Relevant to the Choice of Second-Generation (2-G) Tyrosine Kinase Inhibitor (TKI) for the Treatment of Chronic Myeloid Leukemia (CML) in the United States Using Real-World Claims Databases

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Hematology, 2018

    Published in: Blood